Crossmark

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Crossref DOI link: https://doi.org/10.1136/jitc-2022-006127

Published Online: 2023-02-01

Published Print: 2023-02

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Ready, Neal E https://orcid.org/0000-0003-4414-9432
Audigier-Valette, Clarisse

Goldman, Jonathan W

Felip, Enriqueta

Ciuleanu, Tudor-Eliade

Rosario García Campelo, María

Jao, Kevin

Barlesi, Fabrice

Bordenave, Stéphanie

Rijavec, Erika

Urban, Laszlo

Aucoin, Jean-Sébastien

Zannori, Cristina

Vermaelen, Karim

Arén Frontera, Osvaldo

Curioni Fontecedro, Alessandra

Sánchez-Gastaldo, Amparo

Juan-Vidal, Oscar

Linardou, Helena

Poddubskaya, Elena

Spigel, David R

Ahmed, Samreen

Maio, Michele

Li, Sunney

Chang, Han

Fiore, Joseph

Acevedo, Angelic

Paz-Ares, Luis
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02869789 at ClinicalTrials.gov

Documents that mention this clinical trial

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
https://doi.org/10.1136/jitc-2022-006127
Funding

Funding for this research was provided by:

Bristol Myers Squibb (N/A)
License Information

License valid from 2023-02-01

Document is current

Any future updates will be listed below